Analyst Ratings For Albireo Pharma (NASDAQ:ALBO) (NASDAQ:ALBO)
Today, Wedbush reiterated its Outperform rating on Albireo Pharma (NASDAQ:ALBO) (NASDAQ:ALBO) with a price target of $63.00.
Some recent analyst ratings include
- 3/28/2018-Wedbush Reiterated Rating of Outperform.
- 3/15/2018-Needham & Company LLC initiated coverage with a Buy rating.
- 11/17/2017-Cowen Reiterated Rating of Buy.
- 11/15/2017-Roth Capital initiated coverage with a Buy rating.
- 2/16/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 1/25/2017-William Blair initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Albireo Pharma (NASDAQ:ALBO) (NASDAQ:ALBO)
Albireo Pharma (NASDAQ:ALBO) (NASDAQ:ALBO) has insider ownership of 22.30% and institutional ownership of 29.43%.
- On 1/30/2018 Phase4 Partners Ltd, Major Shareholder, sold 100,000 with an average share price of $34.44 per share and the total transaction amounting to $3,444,000.00.
- On 1/25/2018 Life Sciences Maste Perceptive, Major Shareholder, bought 275,000 with an average share price of $33.00 per share and the total transaction amounting to $9,075,000.00.
- On 12/1/2017 Plc Astrazeneca, Major Shareholder, sold 500,000 with an average share price of $21.40 per share and the total transaction amounting to $10,700,000.00.
- On 12/20/2013 Brian Jg Pereira, Director, sold 4,734 with an average share price of $2.26 per share and the total transaction amounting to $10,698.84.
Recent Trading Activity for Albireo Pharma (NASDAQ:ALBO) (NASDAQ:ALBO)
Shares of Albireo Pharma (NASDAQ:ALBO) closed the previous trading session at 32.71 up +0.51 1.58% with shares trading hands.